Chlamydia pneumoniae (C. pneumoniae)

Chlamydia pneumoniae is a species of Gram-negative, obligate intracellular bacteria that serves as a significant human pathogen responsible for respiratory tract infections such as atypical pneumonia, bronchitis, and sinusitis (StatPearls, 2023). It exhibits a unique developmental cycle alternating between the infectious, metabolically inactive elementary body (EB) and the replicative, metabolically active reticulate body (RB) within host cell inclusions (NCBI, 2022). While primarily recognized for acute respiratory disease, chronic infection has been associated with systemic inflammatory conditions, including atherosclerosis and reactive arthritis, due to its ability to persist within macrophages and vascular smooth muscle cells (PubMed, 2021). Pharmacological treatment focuses on antibiotics that can achieve high intracellular concentrations to reach the pathogen, specifically targeting essential bacterial processes like protein synthesis or DNA replication (Mayo Clinic, 2023). Common therapeutic agents include macrolides, tetracyclines, and certain fluoroquinolones, though the bacteria's ability to enter a dormant state can complicate complete eradication (CDC, 2022).

Other names

Chlamydophila pneumoniaeTWAR agentChlamydia pneumoniae (TWAR)

Antibacterial agents targeting Chlamydia pneumoniae primarily act by inhibiting bacterial protein synthesis through binding to the 30S (tetracyclines) or 50S (macrolides) ribosomal subunits, or by inhibiting DNA gyrase and topoisomerase IV (fluoroquinolones) to prevent DNA replication (StatPearls, 2023).